膦甲酸盐与重组α-A干扰素在体外对人嗜T细胞病毒III型复制的协同抑制作用
Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon.
作者信息
Hartshorn K L, Sandstrom E G, Neumeyer D, Paradis T J, Chou T C, Schooley R T, Hirsch M S
出版信息
Antimicrob Agents Chemother. 1986 Jul;30(1):189-91. doi: 10.1128/AAC.30.1.189.
Abstract
Phosphonoformate and recombinant alpha-A interferon synergistically inhibited the replication of human T-cell lymphotropic virus type III in cultured peripheral blood lymphocytes. T-cell proliferative capability was maintained by this combination, and toxicity was minimal.
摘要
膦甲酸与重组α - A干扰素协同抑制人Ⅲ型嗜T细胞病毒在培养的外周血淋巴细胞中的复制。这种联合用药维持了T细胞的增殖能力，且毒性最小。
相似文献
1
Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon.
Antimicrob Agents Chemother. 1986 Jul;30(1):189-91. doi: 10.1128/AAC.30.1.189.
2
Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.
Lancet. 1985 Jun 29;1(8444):1480-2. doi: 10.1016/s0140-6736(85)92255-x.
3
Inhibition of HTLV-III/LAV replication by foscarnet.
Biochem Pharmacol. 1985 Nov 15;34(22):4075-9. doi: 10.1016/0006-2952(85)90392-2.
4
In vitro inhibition of Herpesvirus sylvilagus by phosphonoacetic acid and phosphonoformate.
Arch Virol. 1980;66(3):261-4. doi: 10.1007/BF01314739.
5
Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro.
Antimicrob Agents Chemother. 1989 May;33(5):663-9. doi: 10.1128/AAC.33.5.663.
6
Synergism among BIOLF-62, phosphonoformate, and other antiherpetic compounds.
Antimicrob Agents Chemother. 1982 Dec;22(6):1026-30. doi: 10.1128/AAC.22.6.1026.
7
Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
Pharmacol Ther. 1982;19(3):387-415. doi: 10.1016/0163-7258(82)90074-2.
8
Inhibitory effects of foscarnet on herpesvirus multiplication in cell culture.
Arch Virol. 1981;68(3-4):203-9. doi: 10.1007/BF01314573.
9
Prospects of therapy for infections with human T-lymphotropic virus type III.
Ann Intern Med. 1985 Nov;103(5):750-5. doi: 10.7326/0003-4819-103-5-750.
10
Mode of action of phosphonoformate as an anti-herpes simplex virus agent.
Biochim Biophys Acta. 1981 Jan 29;652(1):90-8. doi: 10.1016/0005-2787(81)90212-4.
引用本文的文献
1
Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).
Drugs. 1993 May;45(5):637-53. doi: 10.2165/00003495-199345050-00002.
2
Antiviral therapy for human immunodeficiency virus infections.
Clin Microbiol Rev. 1995 Apr;8(2):200-39. doi: 10.1128/CMR.8.2.200.
3
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
Drugs. 1994 Aug;48(2):199-226. doi: 10.2165/00003495-199448020-00007.
4
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.
Antimicrob Agents Chemother. 1987 Feb;31(2):168-72. doi: 10.1128/AAC.31.2.168.
5
Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro.
Antimicrob Agents Chemother. 1987 Oct;31(10):1613-7. doi: 10.1128/AAC.31.10.1613.
6
Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay.
J Clin Microbiol. 1988 Feb;26(2):231-5. doi: 10.1128/jcm.26.2.231-235.1988.
7
Treatment of human immunodeficiency virus infections.
Antimicrob Agents Chemother. 1987 Jun;31(6):839-43. doi: 10.1128/AAC.31.6.839.
8
Activation of interferon-regulated, dsRNA-dependent enzymes by human immunodeficiency virus-1 leader RNA.
Nucleic Acids Res. 1989 Feb 11;17(3):969-78. doi: 10.1093/nar/17.3.969.
9
Anti-human immunodeficiency virus agent 3'-azido-3'-deoxythymidine inhibits replication of Epstein-Barr virus.
Antimicrob Agents Chemother. 1988 Feb;32(2):265-7. doi: 10.1128/AAC.32.2.265.
10
Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine.
Proc Natl Acad Sci U S A. 1987 Nov;84(22):8120-4. doi: 10.1073/pnas.84.22.8120.
本文引用的文献
1
Phenotypic analysis of new world primate mononuclear cell surface antigens.
J Med Primatol. 1983;12(1):30-40.
2
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.
Adv Enzyme Regul. 1984;22:27-55. doi: 10.1016/0065-2571(84)90007-4.
3
Characterization and distribution of nucleic acid sequences of a novel type C retrovirus isolated from neoplastic human T lymphocytes.
Proc Natl Acad Sci U S A. 1981 Mar;78(3):1887-91. doi: 10.1073/pnas.78.3.1887.
4
HTLV-III in the semen and blood of a healthy homosexual man.
Science. 1984 Oct 26;226(4673):451-3. doi: 10.1126/science.6208608.
5
Effect of interferon on retrovirus replication.
Tex Rep Biol Med. 1981;41:603-9.
6
Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.
Ann Intern Med. 1982 May;96(5):549-56. doi: 10.7326/0003-4819-96-5-549.
7
An effect of interferon on the uncoating of murine leukaemia virus not related to the antiviral state.
J Gen Virol. 1980 Dec;51(Pt 2):425-9. doi: 10.1099/0022-1317-51-2-425.
8
Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells.
Transfusion. 1985 Jul-Aug;25(4):308-12. doi: 10.1046/j.1537-2995.1985.25485273806.x.
9
Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients.
Scand J Infect Dis. 1985;17(2):157-63. doi: 10.3109/inf.1985.17.issue-2.06.
10
Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro.
Lancet. 1985 Mar 16;1(8429):602-4. doi: 10.1016/s0140-6736(85)92144-0.
Zotero 插件